IQ-Meter, IQ-SurgiView, IQ-Flow and IQ-Universe are in development, with launch expected in early 2027. These technologies have not been cleared by the U.S. Food and Drug Administration (FDA) and are ...

Good morning!Until a while ago, were there any of you who were told, “You have chronic gastritis”?Chronic gastritis is, ...

As a military veteran, I have been trained to face difficult circumstances. But this time, the battle was inside my own body.

A retrospective cohort study finds that routine endoscopic and CT response assessments show only limited ability to predict ...

Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO ® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance ...

SanaHeal has developed a biologically compatible adhesive that sticks to wet tissues to simplify a variety of surgeries.

Learn the warning signs of oesophagitis and the potential complications of leaving it untreated ...

I will start with the conclusion. As of today, there are 104 days left until the Nephrology Specialist Exam (written exam on ...

Japan's Takeda Pharmaceutical Co. Ltd. ( TAK ,4502.T) announced Monday positive new data from VERDICT (NCT04259138), a Phase 4 ENTYVIO clinical trial, in ulcerative colitis or UC-related complication.

A landmark review reveals how artificial intelligence and integrative multi-omics are transforming host-microbiome research, ...

AstraZeneca and Amgen present positive results from phase III CROSSING trial of Tezspire in patients with symptomatic and uncontrolled eosinophilic esophagitis at United European ...

Takeda announces first and only UC treat-to-target trial shows treating to disease clearance vs. symptomatic remission with Entyvio prolongs time to first disease-related complica ...